DUN T1

Orally Administered Drug for Type-1 Diabetes

Health Tech & Life Sciences

Active

Seed Meishar Founded 2017

Website ↗ LinkedIn

Total raised

$45K

Last: Equity crowdfunding 2019-12

Stage

Seed

Founded

2017

Headcount

Meishar

Sector

Health Tech & Life Sciences

About

DUN T1 is an early-stage R&D company that develops an orally administered drug for type 1 diabetes. DUN T1's vision is to develop a proactive approach towards treatment and early diagnosis. DUN T1's novel natural ingredient is patented, safe, and effective.

Funding history · 1 round · $45K total

2019-12

Equity crowdfunding $45K

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development

Target customers

Commerce & RetailDistribution ChannelsDistributorHealthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients

Business model

B2B2C

Highlights

1 Patents

Name	DUN T1
Slug	dun-t1
Type	Israeli Startup
Founded	2017
HQ city	Meishar
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object]
Business models	B2B2C
Target customers	[object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object]
Status	active
Current stage	Seed
Public stage	Seed
Total raised (USD)	45,000
Last round	Equity crowdfunding (2019-12)
Website	https://www.dunica.info/
Israeli Companies Registrar	516033875

Name	Role	LinkedIn
Daniella Givon
Dr. Avi
Avi Raveh
Prof. Marianna
Marianna Rachmiel
Urs Wiedemann
Dr. Urs
Raanan Margalit
Nadav Shraibom
Yaniv Aronovich
Amir Tirosh
Prof. Amir
Kfir Lapid

DUN T1

About

Funding history · 1 round · $45K total

Sectors & technology

Highlights

Tags

DUN T1 — Full Company Profile (machine-readable)

About

Facts

Funding rounds (1)

Team (13)

About

Funding history · 1 round · $45K total

Sectors & technology

Highlights

Tags

Generate Slim Page